EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

A BALIMONT Multi-Strain Probiotic Platform for Enhancing IgA-Associated Mucosal Immunity: Formulation Optimization and Preclinical Evaluation

Anas Ziraoui, Arabella Sinclair, Jaxon Cole

International Journal of Agriculture and Food Sciences Research · 29.04.2026 · 4 (1) · 67-75

DOI: 10.62051/ijafsr.v4n1.06 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Agriculture and Food Sciences Research, online erschienen am 29.04.2026. Verfasst von Anas Ziraoui und 2 weiteren Autor:innen. Die Arbeit nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Secretory immunoglobulin A (sIgA) is central to epithelial defense and host-microbe homeostasis. Probiotic products positioned for immune support frequently underperform when strain selection, storage resilience, and intestinal delivery are not optimized.

Methods

We reorganized a formulation-development and preclinical dataset describing the BALIMONT immune-support platform and integrated representative published evidence on IgA-oriented probiotic, postbiotic, and prebiotic interventions. The BALIMONT system combined Bifidobacterium bifidum ATCC 29521, Bifidobacterium longum DSM 20219, and Lacticaseibacillus rhamnosus ATCC 7469 with a heat-inactivated Lactococcus lactis-derived postbiotic fraction, a prebiotic support matrix, and staged protective encapsulation.

Results

Within the development dataset, the 2:2:2 tri-strain ratio yielded the strongest in vitro response, with secretory IgA of 21.35 μg/mL and probiotic proliferation of 5.62-fold. A 1:1 postbiotic-to-probiotic cell-count ratio maximized both IgA induction and 30-day viable-count retention. In mice, the 200 mg/kg BALIMONT group exceeded a same-category comparator by 39.68% for serum total IgA, 56.52% for intestinal mucosal sIgA, and 53.01% for fecal sIgA. Viable-count retention remained 86.72% after 6 months at 25°C/60% RH. Published clinical and translational evidence further supports the biological plausibility of IgA-associated mucosal benefits from probiotic and synbiotic strategies.

Conclusions

The BALIMONT platform can be interpreted as a rationally balanced probiotic-postbiotic system in which strain synergy, postbiotic complementation, prebiotic support, and staged delivery converge on IgA-associated mucosal immunity. These findings support continued translational development and justify subsequent human validation.

Zitieren

APA

Ziraoui, A., Sinclair, A., & Cole, J. (2026). A BALIMONT Multi-Strain Probiotic Platform for Enhancing IgA-Associated Mucosal Immunity: Formulation Optimization and Preclinical Evaluation. International Journal of Agriculture and Food Sciences Research, 4(1), 67-75. https://doi.org/10.62051/ijafsr.v4n1.06

Vancouver

Ziraoui A, Sinclair A, Cole J. A BALIMONT Multi-Strain Probiotic Platform for Enhancing IgA-Associated Mucosal Immunity: Formulation Optimization and Preclinical Evaluation. International Journal of Agriculture and Food Sciences Research. 2026;4(1):67-75. doi:10.62051/ijafsr.v4n1.06

BibTeX
@article{Ziraoui2026,
  author = {Ziraoui, Anas and Sinclair, Arabella and Cole, Jaxon},
  title = {A BALIMONT Multi-Strain Probiotic Platform for Enhancing IgA-Associated Mucosal Immunity: Formulation Optimization and Preclinical Evaluation},
  journal = {International Journal of Agriculture and Food Sciences Research},
  year = {2026},
  volume = {4},
  number = {1},
  pages = {67--75},
  doi = {10.62051/ijafsr.v4n1.06}
}
Kostenlos starten →